Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
Satellos Health Inc. announced the granting of a composition of matter patent for its lead therapeutic candidate, Forazapadin, which is expected to enhance its pipeline as it moves into Phase 2 trials. This patent will secure U.S. market exclusivity until September 6, 2044, ensuring that the company maintains a competitive edge in the biotechnology space.
- Forazapadin shows promise in treating muscle-wasting diseases.
- Patent protects innovative formulation and delivery methods.
- Potential market for myopathies exceeding $15B by 2033.
- Company bolsters IP portfolio.
Why it matters: This patent represents a significant milestone for Satellos, as it not only strengthens their market position but also demonstrates the innovative capabilities of their research, appealing to potential investors and partners.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.